ISSN: 2278-0238

Международный журнал исследований и разработок в области фармации и наук о жизни

Открытый доступ

Наша группа организует более 3000 глобальных конференций Ежегодные мероприятия в США, Европе и США. Азия при поддержке еще 1000 научных обществ и публикует более 700 Открытого доступа Журналы, в которых представлены более 50 000 выдающихся деятелей, авторитетных учёных, входящих в редколлегии.

 

Журналы открытого доступа набирают больше читателей и цитируемости
700 журналов и 15 000 000 читателей Каждый журнал получает более 25 000 читателей

Абстрактный

The Case Study of Nephrotic Syndrome Control of Hyperlipidemia with Nephrotic Syndrome Using Hmg Coa Inhibitors: A Nested Case Study

Deepak Kumar Punna, Naveen Kumar Bathula

Introduction: The essential of cholesterol control is the use of HMG-COA inhibitors, but very few researches to date have directed on using what subjects accompanying nephrotic disease put oneself in the place of another cardiovascular occurrence.

Objective: To judge whether either HMG-COA inhibitors situation impacts the consequences of cardiovascular occurrence accompanying nephrotic condition.

Design: A sole center backward-looking reside case-control study resolved dossier from Vijaya Krishna multispecialty hospital, SVR kidney center, Area Hospital Suryapet.

Patients: Patient investigated accompanying nephrotic disease from January 1st, 2022 to December 31st, 2022

Measurement and main results: The research group contained 350 NS victims in total. At the judgment of the practical ending, 65 of these inmates were raised to have heart failure (CVD), and 2 CVD-free controls were contained by 1:2 corresponding accompanying common, age, and index period. To competition the criterion traits of the cases and controls (1:1), the weakness score corresponding was acted. The square test was run utilizing the patient's habit as an uncovering determinant, and a twofold logistic reversion study was approved to examine the friendship between the distance of HMG-COA inhibitors situation cure and cardiovascular occurrences. Additionally, subgroup studies for suitable determinants were completed activity. The square test told that HMG-COA inhibitors situation drug was essentially connected to a decrease in inmates' risk of CVD. NS abated as the distance of HMG-COA inhibitors situation raised (OR = 0.82 [95% CI 0.73– 0.89], p < 0.001).

Conclusions: For NS patients with dyslipidemia, HMG-COA inhibitor therapy may be used to decrease CVD risk, and extended treatment was associated with more significant risk reduction.